LIGAND PHARMACEUTICALS INC

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

LGND$314.16+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except par value)

	June 30, 2024	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$18,139	$22,954
Short-term investments	208,793	147,355
Accounts receivable, net	37,481	32,917
Inventory	18,672	23,969
Income taxes receivable	—	6,395
Prepaid expenses	1,911	1,182
Current derivative assets	20,141	—
Other current assets	7,122	2,657
Total current assets	312,259	237,429
Intangible assets, net	283,162	299,606
Goodwill	105,250	103,370
Long-term portion of financial royalty assets, net	80,481	62,291
Noncurrent derivative assets	34,505	3,531
Property and equipment, net	14,970	15,607
Operating lease right-of-use assets	7,403	6,062
Finance lease right-of-use assets	3,085	3,393
Equity method investment in Primrose Bio	2,437	12,595
Other investments	10,741	36,726
Deferred income taxes, net	190	214
Other assets	11,922	6,392
Total assets	$866,405	$787,216
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$1,793	$2,427
Accrued liabilities	12,171	12,467
Income taxes payable	2,091	—
Deferred revenue	1,196	1,222
Current contingent liabilities	146	256
Current operating lease liabilities	1,156	403
Current finance lease liabilities	12	7
Total current liabilities	18,565	16,782
Long-term deferred revenue	2,696	1,444
Long-term contingent liabilities	4,052	2,942
Long-term operating lease liabilities	6,415	5,755
Deferred income taxes, net	30,128	31,622
Other long-term liabilities	29,351	27,758
Total liabilities	91,207	86,303
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2024 and December 31, 2023	—	—
Common stock, $0.001 par value; 60,000 shares authorized; 18,103 and 17,556 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	19	18
Additional paid-in capital	238,870	198,696
Accumulated other comprehensive loss	(935)	(817)
Retained earnings	537,244	503,016
Total stockholders' equity	775,198	700,913
Total liabilities and stockholders' equity	$866,405	$787,216

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.